Drug discontinuation: Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection (RECARBRIO)
FDA lists 1 presentation as To Be Discontinued. Companies: Merck Sharp & Dohme LLC.
- Published by source
- 2026-09-09
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Merck Sharp & Dohme LLC
- Products
- Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection RECARBRIO
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- To be discontinued on or near late September 2026.
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-09-09
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1020 | new | 2026-10-22 | 7d167e69285f…ffa46b | 37a5acb6371e…50e48f |
Chain head: #1076 8ad5adc30b9b…88ce20